[{"id":"e8b0660b-2ef5-478d-99a4-a00b7c8e97b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05347212","created_at":"2022-04-26T13:53:53.510Z","updated_at":"2024-07-02T16:35:20.802Z","phase":"Phase 2","brief_title":"Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla","source_id_and_acronym":"NCT05347212","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/22/2022","start_date":" 09/22/2022","primary_txt":" Primary completion: 07/16/2027","primary_completion_date":" 07/16/2027","study_txt":" Completion: 07/16/2027","study_completion_date":" 07/16/2027","last_update_posted":"2024-02-06"},{"id":"0e03b96b-6a8e-4062-b8be-5ef1699f84a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03274258","created_at":"2021-01-18T16:10:16.279Z","updated_at":"2024-07-02T16:35:23.075Z","phase":"Phase 2","brief_title":"Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma","source_id_and_acronym":"NCT03274258","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-18"},{"id":"eb78ca75-84dc-42fc-9d06-f04752556eba","acronym":"NCI-2018-01292","url":"https://clinicaltrials.gov/study/NCT03587662","created_at":"2021-01-18T17:38:43.114Z","updated_at":"2024-07-02T16:35:23.938Z","phase":"Phase 2","brief_title":"Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03587662 - NCI-2018-01292","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • doxorubicin hydrochloride • Ninlaro (ixazomib) • daunorubicin • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/17/2018","start_date":" 08/17/2018","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"}]